C hemotherapy-induced neutropenia is a treatment side effect with several notable consequences for patients with cancer. The most important is increased likelihood of infection, particularly when the absolute neutrophil count falls below 500/mm 3 . More than 60,000 patients with cancer were hospitalized for neutropenia in 1999, with a corresponding 7% inpatient mortality rate (Caggiano, Weiss, Rickert, & Linde-Zwirble, 2005) . In addition, neutropenia is a dose-limiting factor for many regimens and may compromise optimal cancer treatment by requiring dose reduction or delay (Chang, 2000; Crawford et al., 1991; Elting, 1998; Pettengell et al., 1992) , both of which can impact disease progression and long-term survival (Bonadonna & Valagussa, 1981; Glaspy, Hackett, Flyer, Dunford, & Liang, 2001) .
Neutropenia complications can adversely affect health-related quality of life (HRQOL) (Nirenberg et al., 2006a (Nirenberg et al., , 2006b Padilla & Ropka, 2005) . For example, patients with febrile neutropenia had worse symptom profiles than patients without neutropenia for abdominal pain, anorexia, asthenia, dehydration, fatigue, rigors, and vomiting (Glaspy et al., 2001) . Similar patterns have been shown in patients with severe afebrile neutropenia, although those results were nonsignificant trends (Glaspy et al., 2001) . Another investigation showed greater symptom burden for patients with neutropenia grades 3-4 compared to those with grades 0-2; symptoms included depression, physical symptom distress, social limitations and isolation, and limitations on normal physical activities (Fortner, Houts, & Schwartzberg, 2006) .
To date, few self-report instruments are sensitive to changes in HRQOL specific to neutropenia. One measure, the Functional Assessment of Cancer Therapy-Neutropenia Subscale (FACT-NS) (Calhoun, Chih-Hung, Welshman, & Cella, 2002; Wagner et al., 2008) , was designed to assess HRQOL specific to neutropenia and has demonstrated good psychometric properties. However, the FACT-NS has been unable to Design: Known-groups methodology and self-report instrument validation.
Setting: A large community oncology practice in Memphis, TN.
Sample: 424 patients with cancer in four samples.
Methods: All patients in the first three samples were assessed at baseline of chemotherapy administration and at a point analogous to midcycle. The fourth sample underwent a cross-sectional evaluation of the ability of the PCM-N to distinguish patients with febrile neutropenia, severe afebrile neutropenia, and no neutropenia.
Main Research Variables: PCM-N score, grade of neutropenia, and febrile status.
Findings: Internal consistency reliability and factor analysis supported the single additive scale structure of the 13 items of the PCM-N. The PCM-N demonstrated good knowngroups validity and was able to distinguish patients with grades 3-4 neutropenia from those with grades 0-2. The tool also was able to distinguish patients with febrile neutropenia, severe afebrile neutropenia, and no neutropenia. Receiver operating characteristic analyses provided a psychometrically based threshold score.
Conclusions:
The PCM-N is a reliable and valid instrument sensitive to changes in HRQOL associated with moderateto-severe chemotherapy-induced neutropenia.
Implications for Nursing: Nurses can use the PCM-N as a rapid and cost-effective tool for monitoring symptoms of neutropenia in patients with cancer. use a single time point score to differentiate patients who had grades 3-4 neutropenia from those who did not, and the tool has not been validated on a broad demographic sample (Wagner et al., 2008) . In addition, whether the FACT-NS will be useful as an outcome measure or a clinical symptom screener is unclear Article This material is protected by U.S. copyright law. Unauthorized reproduction or online display is prohibited. To purchase quantity reprints, e-mail reprints@ons.org.
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